

SENATE
STATE OF MINNESOTA
NINETY-SECOND SESSION

S.F. No. 803

(SENATE AUTHORS: KORAN, Bigham, Wiklund and Tomassoni)

DATE	D-PG	OFFICIAL STATUS
02/11/2021	312	Introduction and first reading Referred to Health and Human Services Finance and Policy
02/15/2021	401	Authors added Bigham; Wiklund
03/01/2021	626	Author added Tomassoni See HF2128, Art. 3, Sec. 29, 38

1.1 A bill for an act

1.2 relating to health; modifying the medical cannabis program; allowing combustion

1.3 of dried raw cannabis by patients age 21 or older; amending Minnesota Statutes

1.4 2020, sections 152.22, subdivision 6; 152.29, subdivision 3.

1.5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 Section 1. Minnesota Statutes 2020, section 152.22, subdivision 6, is amended to read:

1.7 Subd. 6. **Medical cannabis.** (a) "Medical cannabis" means any species of the genus

1.8 cannabis plant, or any mixture or preparation of them, including whole plant extracts and

1.9 resins, and is delivered in the form of:

1.10 (1) liquid, including, but not limited to, oil;

1.11 (2) pill;

1.12 (3) vaporized delivery method with use of liquid or oil ~~but which does not require the~~

1.13 ~~use of dried leaves or plant form; or;~~

1.14 (4) combustion with use of dried raw cannabis; or

1.15 ~~(4)~~ (5) any other method, ~~excluding smoking,~~ approved by the commissioner.

1.16 (b) This definition includes any part of the genus cannabis plant prior to being processed

1.17 into a form allowed under paragraph (a), that is possessed by a person while that person is

1.18 engaged in employment duties necessary to carry out a requirement under sections 152.22

1.19 to 152.37 for a registered manufacturer or a laboratory under contract with a registered

1.20 manufacturer. This definition also includes any hemp acquired by a manufacturer by a hemp

1.21 grower as permitted under section 152.29, subdivision 1, paragraph (b).

2.1 Sec. 2. Minnesota Statutes 2020, section 152.29, subdivision 3, is amended to read:

2.2 Subd. 3. **Manufacturer; distribution.** (a) A manufacturer shall require that employees
2.3 licensed as pharmacists pursuant to chapter 151 be the only employees to give final approval
2.4 for the distribution of medical cannabis to a patient. A manufacturer may transport medical
2.5 cannabis or medical cannabis products that have been cultivated, harvested, manufactured,
2.6 packaged, and processed by that manufacturer to another registered manufacturer for the
2.7 other manufacturer to distribute.

2.8 (b) A manufacturer may distribute medical cannabis products, whether or not the products
2.9 have been manufactured by that manufacturer.

2.10 (c) Prior to distribution of any medical cannabis, the manufacturer shall:

2.11 (1) verify that the manufacturer has received the registry verification from the
2.12 commissioner for that individual patient;

2.13 (2) verify that the person requesting the distribution of medical cannabis is the patient,
2.14 the patient's registered designated caregiver, or the patient's parent, legal guardian, or spouse
2.15 listed in the registry verification using the procedures described in section 152.11, subdivision
2.16 2d;

2.17 (3) assign a tracking number to any medical cannabis distributed from the manufacturer;

2.18 (4) ensure that any employee of the manufacturer licensed as a pharmacist pursuant to
2.19 chapter 151 has consulted with the patient to determine the proper dosage for the individual
2.20 patient after reviewing the ranges of chemical compositions of the medical cannabis and
2.21 the ranges of proper dosages reported by the commissioner. For purposes of this clause, a
2.22 consultation may be conducted remotely using a videoconference, so long as the employee
2.23 providing the consultation is able to confirm the identity of the patient, the consultation
2.24 occurs while the patient is at a distribution facility, and the consultation adheres to patient
2.25 privacy requirements that apply to health care services delivered through telemedicine;

2.26 (5) properly package medical cannabis in compliance with the United States Poison
2.27 Prevention Packing Act regarding child-resistant packaging and exemptions for packaging
2.28 for elderly patients, and label distributed medical cannabis with a list of all active ingredients
2.29 and individually identifying information, including:

2.30 (i) the patient's name and date of birth;

2.31 (ii) the name and date of birth of the patient's registered designated caregiver or, if listed
2.32 on the registry verification, the name of the patient's parent or legal guardian, if applicable;

3.1 (iii) the patient's registry identification number;

3.2 (iv) the chemical composition of the medical cannabis; and

3.3 (v) the dosage; and

3.4 (6) ensure that the medical cannabis distributed contains a maximum of a 90-day supply
3.5 of the dosage determined for that patient.

3.6 (d) A manufacturer shall require any employee of the manufacturer who is transporting
3.7 medical cannabis or medical cannabis products to a distribution facility or to another
3.8 registered manufacturer to carry identification showing that the person is an employee of
3.9 the manufacturer.

3.10 (e) A manufacturer shall distribute medical cannabis in dried raw cannabis form only
3.11 to a patient age 21 or older, or to the registered designated caregiver, parent, legal guardian,
3.12 or spouse of a patient age 21 or older.